Insider Transactions Reported by 21 Insiders of Viridian Therapeutics, Inc.\DE

Symbol
VRDN on Nasdaq
Industry
Pharmaceutical Preparations
Location
Waltham, MA

Insiders trading volume in the past year

Viridian Therapeutics, Inc.\DE executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Fairmount Funds Management LLC Director, 10%+ Owner $86.1M +$10M +13.1% Oct 23, 2025
Frazier Life Sciences Public Fund, L.P. 10%+ Owner $31.6M Sep 23, 2021
Jonathan Violin Chief Executive Officer, Director $10.1M Feb 2, 2023
Scott Myers Chief Executive Officer, Director $5.45M Apr 12, 2023
Stephen F. Mahoney President and CEO, Director $2.22M Mar 3, 2025
Thomas W. Beetham Chief Operating Officer $1.02M Mar 3, 2025
Lara Meisner Chief Legal Officer $629K Jun 15, 2023
Seth Harmon Chief Financial Officer $587K Mar 3, 2025
Jennifer Tousignant Chief Legal Officer $484K Mar 3, 2025
Thomas Ciulla Chief Medical Officer $16K Feb 5, 2024
Sarah Gheuens Director Jul 1, 2025
Jeffrey Robert Ajer Director Jul 1, 2025
Radhika Tripuraneni Chief Medical Officer Mar 10, 2025
Tomas Kiselak Director Jul 1, 2025
Arlene Morris Director Jul 1, 2025
Jennifer K. Moses Director Jul 1, 2025
Christopher W. Cain Director Jul 1, 2025
Barrett Katz Chief Medical Officer Feb 8, 2023
Carrie Melvin Coo Feb 8, 2023
Kristian Humer CFO and CBO Feb 8, 2023
Peter Evan Harwin Director Jun 26, 2024

Recent Insider Transactions by Companies or Individuals for Viridian Therapeutics, Inc.\DE

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.